Efficacy of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Non-small Cell Lung Cancer
Objective To study the value of first-line treatment of advanced non-small cell lung cancer(NSCLC)with anlotinib combined with chemotherapy.Methods A retrospective analysis was conducted on the data of 90 patients with advanced NSCLC admitted to the Fifth Affiliated Hospital of Zhengzhou University from March 2018 to May 2022.Among them,45 patients who received first-line chemotherapy alone were included in the control group,and 45 patients who received combined treatment with anlotinib were included in the observation group.Both groups were treated continuously for 4 chemotherapy cycles.The treatment efficacy,thelevel of tumor marker levels[cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),neuron-specific enolase(NSE),carcinoembryonic antigen(CEA)],survival status,and incidence of adverse reactions were treated in the two groups.Results After treatment,the total effective rate of the observation group was higher than that of the control group(P＜0.05).Before treatment,there was no statistically difference in CYFRA21-1,NSE,and CEA between the two groups(P＞0.05),after treatment,CYFRA21-1,NSE,and CEA decreased in both groups,and the observation group was lower than the control group(P＜0.05).The survival time of the observation group was longer than that of the control group,and the survival rate was higher than that of the control group(P＜0.05).During the treatment period,there was no statistically difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Anlotinib combined with chemotherapy in the first-line treatment of advanced NSCLC can further improve the treatment effect,reduce the level of tumor markers,help prolong patient survival time,and do not increase toxic side effects,with good safety.
万方数据
维普
